Deep Track Capital LP Purchases New Stake in Novavax, Inc. (NASDAQ:NVAX)

Deep Track Capital LP acquired a new position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,000,000 shares of the biopharmaceutical company's stock, valued at approximately $16,080,000. Deep Track Capital LP owned about 1.25% of Novavax at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Spire Wealth Management acquired a new stake in shares of Novavax in the 4th quarter worth about $29,000. New Age Alpha Advisors LLC purchased a new position in shares of Novavax during the fourth quarter valued at approximately $35,000. KBC Group NV grew its holdings in Novavax by 97.0% during the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 3,917 shares in the last quarter. TigerOak Management L.L.C. purchased a new stake in Novavax in the 4th quarter valued at $86,000. Finally, AlphaQuest LLC boosted its holdings in Novavax by 290.1% during the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 7,940 shares during the last quarter. 53.04% of the stock is owned by institutional investors.

Novavax Stock Down 3.2 %

Shares of NVAX stock opened at $6.07 on Wednesday. The firm has a market cap of $976.32 million, a P/E ratio of -2.69, a PEG ratio of 2.85 and a beta of 3.21. The company has a 50 day moving average of $6.97 and a 200-day moving average of $8.10. Novavax, Inc. has a 12-month low of $4.43 and a 12-month high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to analysts' expectations of $85.48 million. During the same period in the prior year, the business earned ($1.44) earnings per share. As a group, equities analysts expect that Novavax, Inc. will post -1.46 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on NVAX shares. BTIG Research initiated coverage on shares of Novavax in a report on Friday, February 28th. They issued a "buy" rating and a $19.00 target price for the company. TD Cowen raised shares of Novavax to a "hold" rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Novavax presently has a consensus rating of "Hold" and an average target price of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.